Addressing the Challenges in Alzheimer's Disease Diagnosis and Management
Alzheimer’s disease (AD) is the leading cause of cognitive impairment and dementia in older individuals (≥ 65 years) throughout the world. In the United States (U.S.), more than 6 million individuals carry this diagnosis, with many yet to be diagnosed. AD follows a prolonged, progressive disease course that begins with pathophysiological changes years before any clinical manifestations are observed. Individuals harboring such changes may have no symptoms or may exhibit clinical manifestations varying from memory lapses to severe and debilitating loss of memory and cognitive function. There are several clinical gaps including the use of biomarkers in AD diagnosis, knowledge of new and emerging disease-modifying treatments, and multidisciplinary care coordination in early AD. Through an interactive educational initiative bringing together AD experts and clinicians involved in AD care, we aim to educate all those involved to improve the care of patients with early AD.<br> <img src="https://s3.amazonaws.com/media.gathered.com/author/medicallogix/jhu-logo.jpg" width="200" alt="John Hopkins Medicine Logo" title="John Hopkins Medicine Logo">
Addressing the Challenges in the Multidisciplinary Care of Patients with High-Risk NMSC
Non-melanoma skin cancers (NMSC) represent a class of heterogeneous cutaneous malignancies including basal cell carcinoma (BCC), cutaneous squamous cell carcinoma (cSCC), Merkel cell carcinoma (MCC), and rarer skin cancers. Accounting for one third of all cancer diagnoses, NMSCs are the most diagnosed malignancies in the world. It is estimated that 5 million BCCs and 1 million cases of SCC are diagnosed every year in the United States. Of these, high-risk SCC and BCC are relatively rare, while MCC, by its nature, is always considered high risk. Despite their relative rarity, high-risk NMSCs have a disproportionate impact on patient outcomes. The Gather-ed small group social learning platform will provide participating clinicians within each group with the opportunity, over a six-week period, to complete foundational materials asynchronously, and to engage with their colleagues and peers involved in the management of high-risk NMSC through live Group Leader-led synchronous interactions focused on areas of greatest concern of the group members, with peer-to-peer exchanges further encouraged in group case-based challenges.<br> <img src="https://s3.amazonaws.com/media.gathered.com/author/medicallogix/Screenshot%202025-11-10%20at%205.17.45%20PM.png" width="200" alt="John Hopkins Medicine Logo" title="John Hopkins Medicine Logo">
Addressing the Impact of COVID-19 on MS Care
Since the beginning of the COVID-19 pandemic, there have been reservations regarding the risks of using immunosuppressive or immunomodulating agents to treat patients with multiple sclerosis (MS) in case these treatments increase infectious disease risk or reduce vaccine efficacy. Many MS patients take disease-modifying therapies (DMTs) to prevent new symptoms such as muscle weakness, poor coordination, and/or impaired vision while mitigating disease progression. For many years, the treatment paradigm has been to “treat early and never stop”, but given issues that arose during the COVID-19 pandemic, this idea became much more challenging. While it appears we are in a nadir with respect to COVID infections, the risk of COVID remains and is of particular concern for our patients with MS. MS treatment in the context of COVID-19 risk or infection has been exceptionally challenging. Accordingly, healthcare providers have had reservations and concerns regarding deciding what are the safest and most effective treatment strategies taking into consideration all of the risks and potential complications when addressing both MS and COVID-19. Clinicians caring for patients with MS require educational programs to stay informed of the recommended best use of DMTs and to be aware of the latest guidelines for safely treating MS in the context of COVID-19. This collaborative social learning platform establishes a network of providers who can support each other locally, as well as those from different communities, with the goal of learning and sharing best practices that will improve outcomes for patients with MS in the context of COVID-19.<br> <img src="https://s3.amazonaws.com/media.gathered.com/author/medicallogix/jhu-logo.jpg" width="200" alt="John Hopkins Medicine Logo" title="John Hopkins Medicine Logo">
Advanced Endometrial Cancer in the Immunotherapy Age
Endometrial cancer is among the few cancers increasing in incidence and mortality in the United State and remains the most common gynecologic cancer diagnosed. To improve clinical outcomes, clinicians treating patients with endometrial cancer need to understand the molecular classification of the disease, the newest guidelines on management, and the evidence underlying these recommendations. Along with this, clinicians must be aware of the most effective ways to manage possible adverse events as well as be cognizant of how best to address racial disparities in care. This educational initiative will allow clinicians to learn and discuss these crucial points in diagnosing and managing these patients to increase long-term survival. Given the rapid shift in best practices occurring in this area and the fact that current NCCN Guidelines classify endometrial cancers into 1 of 4 molecular groups, as opposed to the traditional 2 groups, it is important for clinicians to stay up to date as advances in areas such as biomarker research continue to be made. This educational activity allows clinicians to engage in interprofessional discussions with knowledgeable experts and peers to more fully understand how to integrate these new treatment approaches into their day-to-day practice and establish actionable plans to improve outcomes for their patients.<br> <img src="https://s3.amazonaws.com/media.gathered.com/author/medicallogix/jhu-logo.jpg" width="200" alt="John Hopkins Medicine Logo" title="John Hopkins Medicine Logo">
Advancements in Treating Early-Stage Biochemical Recurrence in Hormone-Sensitive Prostate Cancer
This collaborative social learning platform establishes a network of providers who can support each other locally, as well as those from different communities, with the goal of learning and sharing best practices that will improve outcomes for patients with non-metastatic hormone-sensitive prostate cancer (nmHSPC). Prostate cancer is the most common solid cancer in men worldwide. Most men are diagnosed as having localized disease because of the widespread use of prostate-specific antigen screening. Men diagnosed as having clinically localized prostate cancer have multiple disease management options, including active surveillance, surgery, or radiotherapy. After local therapy, the treatment of early-stage non-metastatic biochemical recurrence (BCR) in hormone-sensitive (or castrate-sensitive) prostate cancer (HSPC) is not clear cut and options are limited. Treatment options also differ based on whether the patient has a low-risk or high-risk prostate cancer.<br> <img src="https://s3.amazonaws.com/media.gathered.com/author/medicallogix/jhu-logo.jpg" width="200" alt="John Hopkins Medicine Logo" title="John Hopkins Medicine Logo">
Beyond Clinical Trials: Addressing Real-World Evidence and Challenges in Multiple Myeloma Immunotherapy
Multiple myeloma (MM) is a malignant plasma cell disorder and the second most common blood cancer in the United States (U.S.) Survival has improved markedly with modern therapies – the 5-year survival rate has more than doubled in recent decades – yet myeloma remains incurable, and most patients eventually relapse even after achieving remission. Each successive relapse is harder to treat: response rates drop and remission durations shorten with later treatment lines. Given the importance of RWE in RRMM treatment, clinicians treating these patients should be informed about current RWE publications. This educational initiative establishes impactful small group interactions among hematology/oncology clinicians that will provide the opportunity to comprehensively review, discuss and reflect on RWE related to RRMM and how it may impact the care of their patients. Specifically, during this experience, clinicians will explore a number of important issues related to RWE in RRMM including: a) efficacy disparities between clinical trial data and RWE; b) patient population differences; c) safety profile variations; d) treatment sequencing results; e) integration of novel therapies; and f) identifying optimal therapies for specific patient types.<br> <img src="https://s3.amazonaws.com/media.gathered.com/author/medicallogix/jhu-logo.jpg" width="200" alt="John Hopkins Medicine Logo" title="John Hopkins Medicine Logo">
Bridging the Gap in Dialysis Care - Optimizing Hyperphosphatemia Management and Improving Patient Outcomes
Chronic kidney disease (CKD) is estimated to impact approximately 37 million individuals in the United States (U.S). Furthermore, about 786,000 persons are living with end-stage kidney disease (ESKD) and receive renal replacement therapy, either through maintenance dialysis or kidney transplantation. Hyperphosphatemia, characterized by phosphorus levels in the bloodstream exceeding the normal parameters of 2.5–4.5 mg/dL, constitutes a critical aspect of the mineral and bone disorder associated with CKD. Elevated levels of serum phosphorus facilitate vascular calcification, impair endothelial function, and may play a role in other newly identified mechanisms of cardiovascular toxicity specific to CKD. The treatment of hyperphosphatemia in patients with CKD requiring dialysis is complex and is ideally managed by a multidisciplinary team of care providers including nephrologists, advanced practice providers (APPs), nurses, dietitians, pharmacists, and other healthcare professionals. Evidence suggests that multidisciplinary care models can slow the progression of CKD and improve mortality rates, but gaps remain in the availability and implementation of these models across different healthcare settings. These challenges include dietary management, optimization of dialysis, pharmacological interventions, patient education, addressing adherence concerns, and the need for comprehensive care models. This collaborative social learning platform establishes a network of providers who can support each other locally, as well as those from different communities, with the goal of learning and sharing best practices that will improve outcomes for patients with hyperphosphatemia.<br> <img src="https://s3.amazonaws.com/media.gathered.com/author/medicallogix/jhu-logo.jpg" width="200" alt="John Hopkins Medicine Logo" title="John Hopkins Medicine Logo">
How MS Care Has Evolved Since the COVID-19 Pandemic
As a result of the COVID-19 pandemic, we have learned valuable lessons pertinent to MS care. This includes knowledge about COVID-19 severity and infection risk (especially as it relates to DMT selection), a much greater understanding of how DMTs affect SARS-CoV-2 vaccine responses, ways to potentially optimize vaccine responses, and the role of telemedicine. This program covers some of these major lessons learned about MS care. The Gather-ed collaborative social learning platform establishes a network of providers who can support each other with the goal of learning and sharing best practices that will improve outcomes for patients with MS.<br> <img src="https://s3.amazonaws.com/media.gathered.com/author/medicallogix/jhu-logo.jpg" width="200" alt="John Hopkins Medicine Logo" title="John Hopkins Medicine Logo">
Improving Beta-thalassemia Outcomes
With the increase in the lifespan of patients with beta thalassemia and demographic shifts in the U.S., hematologists are treating more patients with this condition. As such, more education is needed on key topics including disease fundamentals, transitioning patients to adult care, new and emerging therapies, and issues around transfusion.The goal of this educational curriculum, Improving Beta-thalassemia Outcomes, is to establish impactful small group interactions between members of the hematology care team that will, through a variety of collaborative educational experiences, help them to improve disease management and care coordination to yield better outcomes for their patients with Beta-thalassemia.<br> <img src="https://s3.amazonaws.com/media.gathered.com/author/medicallogix/montefiore-einstein.png" width="230" alt="Montefiore Einstein Logo" title="Montefiore Einstein Logo">
